In 2022, in response to updated data from the monarchE clinical trial of adjuvant abemaciclib for node ... on the selection of optimal adjuvant chemotherapy and targeted therapy for early breast ...

Hope S. Rugo, MD, FASCO, discusses how the combination of elacestrant and abemaciclib compares with other treatment options for patients with advanced breast cancer, whether estrogen receptor-positive ...

"Our study reveals that continuing CDK4/6 inhibitors with ET [endocrine therapy] post-progression improves survival compared with ET alone, supporting guidelines against [second-line] chemotherapy ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

ESMO 2024 High-Dose Vitamin D Disappoints in Metastatic CRC: SOLARIS High-dose vitamin D added to chemotherapy failed ... Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be ...

Jaguar Health (JAGX)family company Napo Pharmaceuticals provided an overview of the data from the poster presentation conducted yesterday, ...